Rebate Pass-Through Would Lower, Not Raise, Medicare Spending – PhRMA
Biopharma manufacturers dispute predictions that passing through rebates at the point-of-sale in Medicare Part D would increase government spending. Pharmacy benefit managers argue the policy would violate the Part D statute and the Trade Secrets Act.
You may also be interested in...
Congressional Budget Office agrees with the Office of Management and Budget that passing through negotiated rebates to Medicare Part D beneficiaries at the point-of-sale would significantly increase Medicare spending.
PhRMA President Ubl discusses drug pricing advocacy priorities in Medicare Part D during media briefing.
If 2017 was the year of talk (tweets) on prescription drug pricing policy, 2018 is shaping up to be the year of action.